News and Trends 13 Dec 2017 New Belgian Biotech Secures €27M Series A to Develop Peptide Antibiotics Aelin Therapeutics will develop its Pept-in technology, which could hold the answer to the growing antibiotics resistance crisis. Aelin Therapeutics is a Belgian biotherapeutics company that is hoping to pioneer Pept-in, protein knockdown drugs that could revolutionize the antibiotics field and open up previously undruggable targets. The company was founded by VIB and partner universities […] December 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 30 Nov 2017 Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […] November 30, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2017 British Biotech Gets Ready to Launch a New Antibiotic Drug to Fight Resistance Update (17/11/2017): Motif Bio will raise up to $20M (€17M) in the form of a loan from US firm Hercules Capital. The funds will be used to fund the pre-commercialization stage of iclaprim, a new antibiotic that is expected to be launched in the US in 2019. Originally published on 04/10/2017 Iclaprim is a new antibiotic […] November 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 Spanish Scientists’ Discovery Could be the End of Antibiotic-Resistant Superbugs Superbugs might not be so super for long, as Spanish scientists have found a way to block the mechanisms by which they develop antibiotic resistance. Researchers from the Spanish National Research Council (CSIC) have made a big breakthrough in the battle against antibiotic-resistant bacteria. In a study published in Cell, they designed molecules that block the cellular […] November 15, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 World Antibiotic Awareness Week: Here are Biotech’s Top 5 Strategies to Overcome Resistance This week marks the WHO’s World Antibiotic Awareness Week. We had a look at some of the best work being done by biotechs to fight resistance. An estimated 154 million prescriptions for antibiotics are written each year, but up to 30% are unnecessary. The World Health Organization has set up World Antibiotic Awareness Week to tackle this. This year’s theme is […] November 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 French Biotech Lifted by €7M Series A to Develop New Antibiotics Antabio has taken a step towards tackling antibiotic resistance by securing a €7.3M Series A. The funding will accelerate the company’s candidate through a Phase I clinical trial. Antabio is a French biopharma that focuses on one of the world’s biggest crises – antibiotic resistance. The company has raised €7.3M in Series A of fundraising, which it will use to […] October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2017 EU gives French Biotech €20M to Continue the Fight Against Antibiotic Resistance Da Volterra has been boosted by a €20M loan to speed up the development of solutions for the antibiotic resistance crisis. The French biopharma concentrates on the prevention and treatment of serious infections. This is a big area of interest due to rapidly rising antibiotic resistance. The company has been boosted by a €20M loan from the […] September 22, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 18 Sep 2017 Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […] September 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 14 Sep 2017 Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance? Scientists in the UK and US have identified how in-fighting between bacteria could provide a new treatment for hospital-acquired infections. Clostridium difficile is a common cause of hospital-acquired infections, which kill almost 4,000 people in Europe each year. Scientists at the University of Sheffield, the University of Glasgow, and California-based biotech AvidBiotics Corp have discovered that C. difficile uses nanomolecular […] September 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 France Invests €15M in Developing a New Generation of Antibiotics Deinove has received funding from Bpifrance to work on the discovery of the next generation of antibiotics to fight antibiotic-resistant pathogens. The Investments for the Future Program, operated by the French public investment bank Bpifrance, has granted €14.6M to the Antibiotics against Resistant Infectious Germs (AGIR) project, carried out by the Deinove group in collaboration […] September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic Summit Therapeutics has been awarded the Barda Contract worth up to $62M (€52M) to continue to the development of a new antibiotic for hospital-acquired infections. Summit Therapeutics, a biopharma company operating in the UK and US, has received the Barda Contract, designed to counter public health emergencies. In this case, the money will help to […] September 12, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 Europe Gives the Antibiotic Resistance Fight a Major Cash Injection Six European countries, the UK’s Wellcome Trust and South Africa have committed €56.5M to the GARDP to work on breaking antibiotic resistance. The Global Antibiotic Research and Development Partnership (GARDP) has received this week €56.5M of funding to boost its activity, focused in promoting the development of new antibiotics. The investment comes mainly from Germany, […] September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email